Epizyme (EPZM) Downgraded by BidaskClub

Share on StockTwits

BidaskClub downgraded shares of Epizyme (NASDAQ:EPZM) from a hold rating to a sell rating in a report released on Thursday.

EPZM has been the subject of several other reports. Zacks Investment Research raised Epizyme from a hold rating to a buy rating and set a $15.00 price objective for the company in a report on Tuesday, July 24th. ValuEngine cut Epizyme from a hold rating to a sell rating in a report on Friday, August 3rd. Wedbush lifted their price objective on Epizyme from $20.00 to $25.00 in a report on Friday, May 18th. Morgan Stanley started coverage on Epizyme in a report on Friday, September 7th. They set a weight rating for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $25.00 price objective on shares of Epizyme in a report on Wednesday, June 27th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $21.73.

Shares of EPZM stock opened at $10.15 on Thursday. The firm has a market cap of $677.66 million, a P/E ratio of -4.66 and a beta of 1.81. Epizyme has a 1 year low of $8.61 and a 1 year high of $21.40.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $0.54 million. The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.48) earnings per share. analysts predict that Epizyme will post -2.13 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in EPZM. Point72 Asset Management L.P. increased its position in Epizyme by 525.0% during the first quarter. Point72 Asset Management L.P. now owns 750,000 shares of the biopharmaceutical company’s stock worth $13,313,000 after buying an additional 630,000 shares in the last quarter. Voya Investment Management LLC increased its position in Epizyme by 95.0% during the second quarter. Voya Investment Management LLC now owns 1,182,983 shares of the biopharmaceutical company’s stock worth $16,029,000 after buying an additional 576,436 shares in the last quarter. BlackRock Inc. increased its position in Epizyme by 10.4% during the second quarter. BlackRock Inc. now owns 4,303,720 shares of the biopharmaceutical company’s stock worth $58,315,000 after buying an additional 406,541 shares in the last quarter. Citadel Advisors LLC increased its position in Epizyme by 39.3% during the second quarter. Citadel Advisors LLC now owns 810,119 shares of the biopharmaceutical company’s stock worth $10,977,000 after buying an additional 228,405 shares in the last quarter. Finally, Opaleye Management Inc. increased its position in Epizyme by 292.9% during the second quarter. Opaleye Management Inc. now owns 275,000 shares of the biopharmaceutical company’s stock worth $3,726,000 after buying an additional 205,000 shares in the last quarter. 85.07% of the stock is owned by institutional investors.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Recommended Story: What are the most popular ETFs

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply